US Phthalates Ban Will Add Costs, Says Toy Association
India has imposed anti-dumping duty on a Chinese chemical used in pharma industry and aluminium foil to protect domestic industry from cheap imports.
While an anti-dumping duty of up to $1.63 per kg was imposed on Aluminium foil, up to $8.71 per kg duty was slapped on imports of amoxicillin, used in pharmaceuticals. The duty on both the products would be effective for a period of five years, the finance ministry has said in separate notifications.
The commerce ministry’s investigation arm — Directorate General of Anti-Dumping and Allied Duties (DGAD) — in the separate probe had concluded that these products were dumped into India and that has caused material injury to the domestic industry.
Hindalco Industries, Raviraj Foils and Jindal India had filed the application for an anti-dumping probe into imports of aluminium foil, used for packing of medicines, processed foods and cigarette. Similarly, Aurobindo Pharma had filed the application for an anti-dumping probe on Amoxycillin from China.
Countries initiate anti-dumping probe to determine if the domestic industry has been hurt by flooding of below-cost import. As a counter-measure, they come up with duties under the multilateral WTO regime.
Anti-dumping steps are taken to ensure fair trade and provide a level-playing field to the domestic industry. They are not a measure to restrict import or cause an unjustified increase in cost of products.
2026-09-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
Colombia Makes Preliminary Ruling in Anti-Dumping Investigation into Chinese DOP Imports
-
Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
3M, DuPont and Honeywell Must Face Firefighters’ PFAS Turnout-Gear Lawsuit
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
South Korea Expands Mandatory GMO Labeling to Highly Processed Foods
Recommend Reading
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
U.S. and China Open New High-Level Trade Talks on Tariffs, Critical Minerals and Pharma Investment
-
U.S. Formally Imposes Antidumping and Countervailing Duty Orders on Chinese L-Lysine
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
Costs Strongly Support, China's Gasoline and Diesel Prices Surge
-
Negative Factors Persist, Palm Oil Market Weakens and Declines
-
Insufficient Demand, Cyclohexane Market Maintains Stable Operation Overall in China
-
Polyester Bottle Flakes Show Intraday Volatility and Strength on the 23rd, Closing Higher at Late Trading Hours
-
This Week's PVC Prices Narrowly Declined in China